Literature DB >> 7560659

Ethylene oxide allergy in children with spina bifida.

T Pittman1, J Kiburz, G Steinhardt, J Krock, K Gabriel.   

Abstract

BACKGROUND: Allergic reactions to ethylene oxide (EtO-treated products have occurred in several children with myelomeningoceles.
OBJECTIVE: The object of this study was to define the prevalence and significance of EtO-specific IgE among the children in our myelomeningocele clinic.
METHODS: The study population comprised three groups: children clinic.
METHODS: The study population comprised three groups: children with myelomeningoceles, chronically ill controls (defined as children who had undergone at least three major operations), and well-child controls. Serum specimens were collected from each child, and a commercially available ELISA designed to identify IgE directed against both EtO and latex was performed on the specimens.
RESULTS: Seventeen of 75 (23%) children with myelomeningoceles had antibodies directed against EtO, as did 1 of 26 (4%) chronically ill controls. None of the 25 well controls had detectable levels of anti-EtO IgE. Children with antibodies directed against EtO were more likely to be atopic (p = 0.007) and to have a shunt (p = 0.021) and were markedly more likely to have antibodies directed against latex (p = 0.001). On average they had undergone more shunt revisions and other operations than had children without anti-EtO antibodies.
CONCLUSION: During the period of study no child had anaphylaxis thought to have been due to EtO exposure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560659     DOI: 10.1016/s0091-6749(95)70291-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  1 in total

1.  Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide.

Authors:  Ahmad Hamad; Onyinye I Iweala; Cory Henderson; Shivanshu Madan; George A Stouffer; Scott P Commins; Edwin H Kim
Journal:  J Allergy Clin Immunol Pract       Date:  2018-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.